Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using using monoclonal antibodies against the epidermal growth factor receptor (EGFR)

• 收藏
• 分享

专利权人:

Innocimab Pte Ltd;Oncoscience AG

发明人:

Strumberg, Dirk,Schultheis, Beate,Ebert, Matthias P.,Siveke, Jens,Kerkhoff, Andrea,Hofheinz, Ralf,Behringer, Dirk M.,Schmidt, Wolfgang E.,Goker, Erdem,De Dosso, Sara,Kneba, Michael,Yalcin, Suayib,O

申请号：

AU2016299368

公开号：

AU2016299368A1

申请日:

2016.07.27

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

The present disclosure relates to the field of immunotherapy of cancer, in particular pancreatic ductal adenocarcinoma (PDAC). Means and methods for treatment of a population of PDAC patients suffering from PDAC tumours which express wild-type KRAS, HRAS or NRAS are disclosed. The claimed antibody is Nimotuzumab. The pancreatic cancer preferably does not contain KRAS mutations at position 12, 16, 61, 154.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/